Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/14293
標題: 建立黑色素瘤抗原特異性癌症免疫療法及於小鼠黑色素瘤模式中評估抗腫瘤效果
Establishment of melanoma antigen-specific cancer immunotherapy and evaluation of antitumor effect in a murine melanoma model
作者: 蔣孝儀
Jiang, Shiau-Yi
關鍵字: dog

melanoma
cancer immunotherapy
plasmid
murine melanoma model
黑色素瘤
癌症免疫療法
質體
小鼠黑色素瘤模式
出版社: 獸醫學系暨研究所
引用: Reference Alexander, A.N., Huelsmeyer, M.K., Mitzey, A., Dubielzig, R.R., Kurzman, I.D., MacEwen, E.G., Vail, D.M., 2006. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunology Immunotherapy 55, 433-442. Aronsohn, M.G., Carpenter, J.L., 1990. Distal extremity melanocytic nevi and malignant melanomas in dogs. Journal of the American Animal Hospital Association 26, 605-612. Barrow, C., Browning, J., MacGregor, D., Davis, I.D., Sturrock, S., Jungbluth, A.A., Cebon, J., 2006. Tumor antigen expression in melanoma varies according to antigen and stage. Clinical Cancer Research 12, 764-771. Berd, D., Maguire, H.C., Mccue, P., Mastrangelo, M.J., 1990. Treatment of metastatic melanoma with an autologous tumor-cell vaccine - clinical and immunological results in 64 patients. Journal of Clinical Oncology 8, 1858-1867. Bergman, P.J., 2007. Canine oral melanoma. Clinical Techniques in Small Animal Practice 22, 55-60. Bergman, P.J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., Wulderk, M., Jeffers, Y., Sadelain, M., 2003. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 9, 1284-1290. Bishop, P.W., Menasce, L.P., Yates, A.J., Win, N.A., Banerjee, S.S., 1993. An immunophenotypic survey of malignant melanomas. Histopathology 23, 159-166. Blackwood, L., Dobson, J.M., 1996. Radiotherapy of oral malignant melanomas in dogs. Journal of the American Veterinary Medical Association 209, 98-102. Bolon, B., Mays, M.B.C., Hall, B.J., 1990. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Veterinary Pathology 27, 96-102. Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M., Knapp, D.W., 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224, 388-394. Branda, R.F., Moore, A.L., Mathews, L., McCormack, J.J., Zon, G., 1993. Immune stimulation by an antisense oligomer complementary to the REV gene of HIV-1. Biochemical Pharmacology 45, 2037-2043. Choi, C., Kusewitt, DF., 2003. Comparison of Tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Veterinary Pathology 40, 713-718. Corr, M., Lee, D.J., Carson, D.A., Tighe, H., 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. The Journal of Experimental Medicine 184, 1555-1560. Crooke, S.T., 1995. Delivery of oligonucleotides and polynucleotides. Journal of Drug Targeting 3, 185-190. De las Casas, L.E., Raso, D.S., Baird, D.B., Silverman, J.F., 1998. FNA of malignant melanoma: A brown stain without brown stains? Diagnostic Cytopathology 19, 151-152. Dorn, C.R., Priester, W.A., 1976. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. Journal of the American Veterinary Medical Association 169, 1202-1206. Fang, L., Lonsdorf, A.S., Hwang, S.T., 2008. Immunotherapy for advanced melanoma. Journal of Investigative Dermatology 128, 2596-2605. Fernando, S.S., Johnson, S., Bate, J., 1994. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 26, 16-19. Finocchiaro, L.M., Glikin, G.C., 2008. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Therapy 15, 267-276. Fioretti, D., Iurescia, S., Fazio, V.M., Rinaldi, M., 2010. DNA vaccines: developing new strategies against cancer. Journal of Biomedicine and Biotechnology l, doi:10.1155/2010/174378. Gileadi, U., Gallimore, A., Van der Bruggen, P., Cerundolo, V., 1999. Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology 29, 2213-2222. Gregorevic, P., Blankinship, M.J., Chamberlain, J.S., 2004. Viral vectors for gene transfer to striated muscle. Current Opinion in Molecular Therapeutics 6, 491-498. Guevara-Patino, J.A., Turk, M.J., Wolchok, J.D., Houghton, A.N., 2003. Immunity to cancer through immune recognition of altered self: Studies with melanoma. Advances in Cancer Research, Vol 90, 157-177. Gurunathan, S., Klinman, D.M., Seder, R.A., 2000. DNA vaccines: Immunology, application, and optimization. Annual Review of Immunology 18, 927-974. Harvey, H.J., MacEwen, E.G., Braun, D., Patnaik, A.K., Withrow, S.J., Jongeward, S., 1981. Prognostic criteria for dogs with oral melanoma. Journal of the American Veterinary Medical Association 178, 580-582. Hicks, M.J., Flaitz, C.M., 2000. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncology 36, 152-169. Hohlfeld, R., Engel, A.G., 1994. The immunobiology of muscle. Immunology Today 15, 269-274. Holzhutter, H.G., Frommel, C., Kloetzel, P.M., 1999. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. Journal of Molecular Biology 286, 1251-1265. Hoyt, R.F., Withrow, S.J., 1984. Oral Malignancy in the Dog. Journal of the American Animal Hospital Association 20, 83-92. Kaufmann, O., Koch, S., Burghardt, J., Audring, H., Dietel, M., 1998. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Modern Pathology 11, 740-746. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sakaguchi, K., Appella, E., Yannelli, J.R., Adema, G.J., Miki, T., Rosenberg, S.A., 1994. Identification of a human-melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in-vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America 91, 6458-6462. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., Rosenberg, S.A., 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. Journal of Immunology 154, 3961-3968. Key, M.E., Hanna, M.G., 1981. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor-immunity. I. Synergism between BCG and line 10 tumor-cells in the induction of an inflammatory response. Journal of the National Cancer Institute 67, 853-861. Kim, C.J., Dessureault, S., Gabrilovich, D., Reintgen, D.S., Slingluff, C.L., Jr., 2002. Immunotherapy for melanoma. Cancer control : journal of the Moffitt Cancer Center 9, 22-30. Kozak, M., 1986. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosome. Cell 44, 283-292. Kundig, T.M., Bachmann, M.F., DiPaolo, C., Simard, J.J., Battegay, M., Lother, H., Gessner, A., Kuhlcke, K., Ohashi, P.S., Hengartner, H., et al., 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268, 1343-1347. Kutzler, M.A., Weiner, D.B., 2008. DNA vaccines: ready for prime time? Nature Reviews Genetics 9, 776-788. Lamb, J.R., Skidmore, B.J., Green, N., Chiller, J.M., Feldmann, M., 1983. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. The Journal of Experimental Medicine 157, 1434-1447. Lee, S.W., Li, H., Strong T.V., Moore S.E., Conry, R.M., 2000. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials. Journal of immunotherapy 23, 379-386. Leong, S.P.L., Enders-Zohr, P., Zhou, Y.M., Stuntebeck, S., Habib, F.A., Allen, R.E., Sagebiel, R.W., Glassberg, A.B., Lowenberg, D.W., Hayes, F.A., 1999. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. Journal of Immunotherapy 22, 166-174. Levy, A., Pitcovski, J., Frankenburg, S., Elias, O., Altuvia, Y., Margalit, H., Peretz, T., Golenser, J., Lotem, M., 2007. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cellular Immunology 250, 24-30. Macewen, E.G., 1990. Spontaneous tumors in dogs and cats - models for the study of cancer biology and treatment. Cancer and Metastasis Reviews 9, 125-136. MacEwen, E.G., Kurzman, I.D., Vail, D.M., Dubielzig, R.R., Everlith, K., Madewell, B.R., Rodriguez, C.O., Phillips, B., Zwahlen, C.H., Obradovich, J., Rosenthal, R.C., Fox, L.E., Rosenberg, M., Henry, C., Fidel, J., 1999. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clinical Cancer Research 5, 4249-4258. Marino, D.J., Matthiesen, D.T., Stefanacci, D., Moroff, S.D., 1995a. Evaluation of dogs with digit masses - 117 Cases (1981-1991). Journal of the American Veterinary Medical Association 207, 726-728. Marino, D.J., Matthiesen, D.T., Stefanacci, J.D., Moroff, S.D., 1995b. Evaluation of dogs with digit masses: 117 cases (1981-1991). . Journal of the American Veterinary Medical Association 207, 726-728. Martinez Conesa, C., Alvarez Sanchez, N., Vicente Ortega, V., Garcia Reverte, J., Pascual Carpe, F., Campos Aranda, M., 2009. In vitro and in vivo effect of IFN alpha on B16F10 melanoma in two models: subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice). Biomedicine & Pharmacotherapy 63, 305-312. Miller, A.J., Mihm, M.C., Jr., 2006. Melanoma. The New England Journal of Medicine 355, 51-65. Mitchell, M.S., Harel, W., Kanmitchell, J., Lemay, L.G., Goedegebuure, P., Huang, X.Q., Hofman, F., Groshen, S., 1993. Active specific immunotherapy of melanoma with allogeneic cell lysates - rationale, results, and possible mechanisms of action. Annals of the New York Academy of Sciences 690, 153-166. Mueller, D.L., Jenkins, M.K., Schwartz, R.H., 1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annual Review of Immunology 7, 445-480. Neisig, A., Roelse, J., Sijts, A.J., Ossendorp, F., Feltkamp, M.C., Kast, W.M., Melief, C.J., Neefjes, J.J., 1995. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. Journal of Immunology 154, 1273-1279. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y.S., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D., 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4, 328-332. Orchard, G.E., 2000. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. The Histochemical Journal 32, 475-481. Pardoll, D.M., Beckerleg, A.M., 1995. Exposing the immunology of naked DNA vaccines. Immunity 3, 165-169. Posnett, D.N., Engelhorn, M.E., Lin, Y., Merghoub, T., Duan, F., Wolchok, J.D., Houghton, A.N., 2009. Development of effective vaccines for old mice in a tumor model. Vaccine 27, 1093-1100. Proulx, D.R., Ruslander, D.M., Dodge, R.K., Hauck, M.L., Williams, L.E., Horn, B., Price, G.S., Thrall, D.E., 2003. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary Radiology & Ultrasound 44, 352-359. Ramos-Vara, J.A., Beissenherz, M.E., Miller, M.A., Johnson, G.C., Pace, L.W., Fard, A., Kottler, S.J., 2000. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Veterinary Pathology 37, 597-608. Rassnick, K.M., Ruslander, D.M., Cotter, S.M., Al-Sarraf, R., Bruyette, D.S., Gamblin, R.M., Meleo, K.A., Moore, A.S., 2001. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). Journal of the American Veterinary Medical Association 218, 1444-1448. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H., White, D.E., 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 4, 321-327. Rosenberg, S.A., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H., White, D.E., 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal-cell cancer using high-dose bolus interleukin-2. Journal of the American Medical Association 271, 907-913. Saenger, Y.M., Li, Y., Chiou, K.C., Chan, B., Rizzuto, G., Terzulli, S.L., Merghoub, T., Houghton, A.N., Wolchok, J.D., 2008. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Research 68, 9884-9891. Saleh, F.F., 2005. Cancer vaccine and immunotherapy. Current Pharmaceutical Design 11, 3459-3460. Shackelford, C., Long, G., Wolf, J, Okerberg, C., Herbert, R., 2002. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicological Pathology 30, 93-96. Slingluff, C.L., Jr., Yamshchikov, G.V., Hogan, K.T., Hibbitts, S.C., Petroni, G.R., Bissonette, E.A., Patterson, J.W., Neese, P.Y., Grosh, W.W., Chianese-Bullock, K.A., Czarkowski, A., Rehm, P.K., Parekh, J., 2008. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Annals of Surgical Oncology 15, 3538-3549. Smith, H.A., 2000. Regulation and review of DNA vaccine products. Developmental Biology 104, 57-62. Smith, S.H., Goldschmidt, M.H., McManus, P.M., 2002. A comparative review of melanocytic neoplasms. Veterinary Pathology 39, 651-678. Sparwasser, T., Hultner, L., Koch, E.S., Luz, A., Lipford, G.B., Wagner, H., 1999. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. Journal of Immunology (Baltimore, Md: 1950) 162, 2368-2374. Takahashi, K., Shichijo, S., Noguchi, M., Hirohata, M., Itoh, K., 1995. Identification of Mage-1 and Mage-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Research 55, 3478-3482. Tanaka, M., Kogawa, K., Nishihori, Y., Kuribayashi, K., Nakamura, K., Muramatsu, H., Koike, K., Sakamaki, S., Niitsu, Y., 1997. Suppression of intracellular Cu-Zn SOD results in enhanced motility and metastasis of Meth A sarcoma cells. International Journal of Cancer 73: 187-192. Tanaka, M., Kaneda, Y., Fujii, S., Yamano, T., Hashimoto, K., Huang, S.K., Hoon, D.S., 2002. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Molecular Therapy: The Journal of the American Society of Gene Therapy 5, 291-299. Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E.A., Liewer, U., Biggs, J., Levine, A.J., Huber, C., Koszinowski, U.H., Kloetzel, P.M., Sherman, L.A., 1998. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. The Journal of Experimental Medicine 188, 1017-1028. Theon, A.P., Rodriguez, C., Madewell, B.R., 1997. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. Journal of the American Veterinary Medical Association 210, 778-784. Todoroff, R.J., Brodey, R.S., 1979. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. Journal of the American Veterinary Medical Association 175, 567-571. Triozzi, P.L., Aldrich, W., Allen, K.O., Carlisle, R.R., LoBuglio, A.F., Conry, R.M., 2005. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. Journal of immunotherapy (Hagerstown, Md.: 1997) 28, 382-388. van den Berg, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G., Storm, G., Beijnen, J.H., Hennink, W.E., 2010. Synthetic vehicles for DNA vaccination. Journal of Drug Targeting 18, 1-14. van der Linde-Sipman, J.S., deWit, M.M.L., vanGarderen, E., Molenbeek, R.F., van der Velde-Zimmermann, D., deWeger, R.A., 1997. Cutaneous malignant melanomas in 57 cats: Identification of (amelanotic) signet-ring and balloon cell types and verification of their origin by immunohistochemistry, electron microscopy, and in situ hybridization. Veterinary Pathology 34, 31-38. Velders, M.P., Weijzen, S., Eiben, G.L., Elmishad, A.G., Kloetzel, P.M., Higgins, T., Ciccarelli, R.B., Evans, M., Man, S., Smith, L., Kast, W.M., 2001. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. Journal of immunology (Baltimore, Md.: 1950) 166, 5366-5373. Weber, L.W., Bowne, W.B., Wolchok, J.D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J.J., Houghton, A.N., 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. Journal of Clinical Investigation 102, 1258-1264. Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S.H., Hoon, D.S., 2006. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Molecular therapy : the journal of the American Society of Gene Therapy 13, 194-202. Yellen-Shaw, A.J., Wherry, E.J., Dubois, G.C., Eisenlohr, L.C., 1997. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. Journal of immunology (Baltimore, Md.: 1950) 158, 3227-3234. Zendman, A.J.W., Ruiter, D.J., Van Muijen, G.N.P., 2003. Cancer/testis-associated genes: Identification, expression profile, and putative function. Journal of Cellular Physiology 194, 272-288.
摘要: 黑色素瘤細胞會表現多種分化抗原,包括Melan-A、Tyrosinas及GP 100,而這些分化抗原可當作免疫療法之標靶抗原,引起特異性之免疫反應。本實驗之研究目的為架構出可表現黑色素瘤抗原之質體,作為治療犬黑色素瘤之免疫療法。首先,以PCR方式來合成及增幅包含GP100及Tyrosinase之多抗原結合位序列,作為標靶抗原序列,再將其與可表現綠色螢光蛋白之真核表現質體連結。以螢光顯微鏡及西方墨點法來確認此合成之質體可於真核細胞中表現出抗原及螢光蛋白。而此合成之多抗原結合位質體以三種不同劑量(5, 50, 250 μg)分別以肌肉注射之方式,於C57BL/6J小鼠進行安全性及急性毒性評估,於七天觀察期中並無出現明顯之臨床症狀及副作用。於小鼠黑色素瘤模式中以治療性試驗來評估多抗原結合位質體之抗腫瘤效果,經腫瘤接種後第24天,多抗原結合位質體治療組之腫瘤體積生長受到顯著抑制(*p<0.05)。因此,此多抗原結合位質體可能具有使黑色素瘤消退或增加病患存活時間之潛在效力,但仍需更深入的研究來確認應用於犬黑色素瘤上的效力。
Melanoma cells selectively express a number of differentiation antigens including melan-A, gp100, and tyrosinase that can serve as targets for an immunotherapy strategy. The aim of our study was to construct a melanoma specific antigen expression plasmid as an immunotherapy for canine melanoma. A multiepitope sequence, which modified from a previous study, was generated by annealing of a set of 8 primers by PCR reaction. A plasmid in which expression of the multiepitope sequence of melanoma antigens or fused with the GFP (green fluorescence protein) was constructed. The transient expression of multiepitope-GFP in eukaryotic cells (HEK-293T) was confirmed by fluorescent microscopy and western blot analysis. Evaluation of safety and acute toxicity was performed, and adverse effect was not significant in C57BL6/J mice intramuscularly injected with multiepitope plasmid at three different doses (5, 50, 250 μg) after 7 days of observation. Furthermore, a melanoma model was successfully established in C57BL/6J mice and the therapeutic effect of the plasmid was evaluated on these tumor bearing mice. The growth of tumor volume in the therapeutic group was significant inhibited than the mock group (*p<0.05) and control group (*p<0.05) on day 24. The multiepitope plasmid might be a potential therapy to regress the melanoma or improve survival time of patients and further investigation of multiepitope plasmid on canine melanoma is necessary.
URI: http://hdl.handle.net/11455/14293
其他識別: U0005-2607201019020800
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2607201019020800
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.